Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | PALMARES-2: comparing first-line palbociclib, ribociclib, or abemaciclib in HR+/HER2- aBC

Claudio Vernieri, MD, PhD, Institut National Du Cancer, Milan, Italy, discusses the findings from the PALMARES-2 study, which evaluated the real-world efficacy of the three CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—in combination with endocrine therapy for treating hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC). This multicenter, population-based study analyzed 1850 patients treated across 18 Italian cancer centers. The results indicated that both abemaciclib and ribociclib were associated with better real-world progression-free survival (rwPFS) compared to palbociclib, though no significant difference in efficacy was observed between abemaciclib and ribociclib. The study highlights the varying antitumor efficacy of these drugs and underscores the need for longer follow-up to assess their impact on overall survival. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.